A First Biologic for Psoriatic Arthritis in a New Father With Crohn's Disease
Etanercept is off the table the moment his Crohn's disease enters the conversation. What's left is a genuine choice between a drug that treats both diseases at once and one built specifically for the joint disease that's harder on him today.
Julian P. became a father four months ago, and between broken sleep and a warehouse supervisor job that has him on a concrete floor for ten-hour shifts, he's noticed his joints in a way he never used to. Psoriasis has been part of his life since his twenties, managed with topicals; the new development is real polyarticular joint pain and swelling over the past four months, confirmed as psoriatic arthritis, active enough that his rheumatologist wants to start a first biologic rather than wait through another round of NSAIDs and hope. His medical history carries a second, older diagnosis that shapes today's whole conversation: Crohn's disease, diagnosed five years ago, currently in mild-to-moderate activity on his last colonoscopy, managed but not fully quiet.
That history removes one option before the discussion even starts. Etanercept, effective for joint disease, was tested directly in Crohn's disease by Sandborn and colleagues and failed to beat placebo — it has never shown efficacy for inflammatory bowel disease in a controlled trial and is specifically not used when a patient has active or even historical Crohn's — a real, well-established exclusion, not a theoretical caution. What's left is a genuine choice between two mechanistically different options that both have real claims on him. A monoclonal TNF inhibitor like adalimumab, by contrast with etanercept, has demonstrated efficacy for both joint and bowel disease together, treating his psoriatic arthritis and his Crohn's disease with a single drug. Ustekinumab, an IL-12/23 inhibitor, is independently approved for both psoriatic arthritis and Crohn's disease as well — on the PSUMMIT joint trials and the UNITI induction-and-maintenance program respectively — with a favorable long-term safety profile and a dosing interval — every eight to twelve weeks after induction — that fits a new father's stretched schedule better than an every-other-week injection does. Julian was candid about that last point specifically: between his shift schedule and a baby who still wakes twice most nights, he told his rheumatologist plainly that a drug he might actually forget to take on schedule is a worse drug for him than one with marginally different trial data.
One drug for two diseases, or the stronger drug for one
Once etanercept is off the table for his Crohn's history, adalimumab is the option that actually simplifies his life rather than adding to it — one drug, one injection schedule, treating both his joints and his gut. He's a new father working ten-hour shifts on a concrete floor; a regimen he can actually sustain matters as much as which drug looks marginally stronger on paper for either disease alone.
I'd weigh ustekinumab more heavily than that framing suggests. It's independently approved for both his conditions too, so the "one drug, two diseases" argument doesn't actually favor adalimumab specifically — and its dosing interval, every eight to twelve weeks after induction, fits his schedule at least as well, arguably better, than an every-other-week TNF inhibitor injection. It also sidesteps a real, if uncommon, TNF-inhibitor-specific risk: paradoxical psoriasiform reactions, which would be a genuinely bad outcome in a patient whose presenting disease is psoriatic.
I take the simplicity argument seriously, but "simpler" shouldn't just mean "the drug we reached for first" — on the numbers, ustekinumab is at least as simple and avoids a risk specific to his exact clinical picture.
I want to bring this back to the gut side specifically, since that's the disease I'm actually managing. His Crohn's isn't flaring, but it isn't fully quiet either — mild-moderate activity on his last scope, on mesalamine alone. Both drugs are approved for Crohn's, but they don't carry equally deep evidence there; TNF monoclonal antibodies have a longer, more extensive track record for inducing and maintaining Crohn's remission specifically. Given that his bowel disease is the one condition here that isn't currently well-controlled, I'd let that tip the balance toward adalimumab — not because it's simpler, but because it's the stronger choice for the disease doing the least well right now.
Agreed: start adalimumab, with joint response tracked by his rheumatologist and Crohn's activity reassessed by his gastroenterologist at 3 months, including a plan to escalate GI-directed therapy if colitis activity doesn't improve alongside the biologic.
Not agreed: whether ustekinumab should have been the default choice given its comparable dual approval and better fit with his schedule. The clinical pharmacologist maintains it was a closer call than the final decision suggests and would revisit it directly if his Crohn's disease doesn't respond adequately to adalimumab within the 3-month window.